Vascular endothelium summary statement III: Cancer prevention and control.
The biology of vascular endothelium can be modulated through the use of pharmacologic agents. Whereas this has been explored to reasonable extent in cardiovascular disease, it is clear that the ability to modulate vascular endothelium for the purpose of cancer prevention is in its early stages. Among the unanswered questions, we do not understand under what circumstances such pharmacologic interventions might best be started; nor, how long such interventions might be used for a given individual. We present concepts for further exploration in the use of endothelial-active agents for cancer prevention and control; and, strategies for public health practice and research in this area.
Reed
Eddie
E
Division of Cancer Prevention and Control, NCCDPHP, CoCHP, Centers for Disease Control and Prevention, 4770 Buford Highway, Mailstop K52, Atlanta, GA 30341 USA. Ereed1@cdc.gov
Seffrin
John
J
Giavazzi
Raffaella
R
van Hinsbergh
Victor
V
Madeddu
Paolo
P
D043925:Angiogenesis Inducing Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D035843:Biomedical Research; D004059:Diffusion of Innovation; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D014943:Global Health; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control*; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control*; D015980:Public Health Practice
D043925:Angiogenesis Inducing Agents; D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents